Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BELLWAVE-011: Nemtabrutinib vs ibrutinib or acalabrutinib in untreated CLL/SLL
jRCT2031230697Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- May 2024
- Modality
- Small Molecules
01
Overview
Phase 3, randomised trial of nemtabrutinib in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (2 arms), sponsored by Merck & Co. Primary endpoints: Objective Response Rate (ORR) and Progression-Free Survival (PFS). Started May 2024; status: active, not recruiting.
02
Drugs
nemtabrutinib
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on jRCT2031230697.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230697.